Kidswell Bio Corporation's share price fell 2.3% over the past 5 trading days, closing at ¥168 on 8 September. The company also disclosed that research findings on SHED-OV therapy had been published in an international journal that day.
The share price fell from ¥172 at the 1 September close to ¥168 on 8 September, a decline of 2.3% over the past 5 trading days. It was at one point up 2.44% from the previous day on 8 September, but overall the period lacked a clear direction, with recoveries and pullbacks alternating.
The company disclosed on 1 September that research findings on SHED-OV therapy had been published in an international academic journal, adding a catalyst in the field of regenerative medicine.
According to a summary of the earnings report announced on 13 August 2026, revenue for the first quarter of the fiscal year ending March 2027 was approximately ¥1.3 billion, down 26.2% year on year, while operating profit was approximately ¥200 million, representing an increase. Quarterly net income also rose to approximately ¥200 million.
Information provided indicates that earnings have been on an improving trend over the past 12 quarters, while the equity ratio has fluctuated around its benchmark level. The stated points to monitor for future earnings include the establishment of appropriate supply pricing and sustained cost reductions, as well as progress in new development.